TRK-950 with standard chemo for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, TRK-950, added to standard chemotherapy (ramucirumab and paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has worsened after previous treatment. The goal is to see if this combination can help shrink tumors or slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach or gastroesophageal junction cancer that has spread or cannot be removed with surgery.
- Your cancer has gotten worse during or after at least one prior treatment (e.g., chemotherapy).
- You have not been treated with ramucirumab or paclitaxel before.
- Your tumor sample shows a certain level of a protein called CAPRIN-1 (determined by a special test).
- You are healthy enough to be up and active (ECOG score 0 or 1) and have a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This study tests whether giving treatment based on the specific markers of your tumor can better control advanced stomach cancer. The goal is to match the right therapy to each person's cancer.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs for advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.